Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation

Am J Gastroenterol. 2017 Oct;112(10):1621. doi: 10.1038/ajg.2017.246.

Authors

Brigid S Boland^{1

2}, Marc A Riedl³, Mark A Valasek⁴, Sheila E Crowe², William J Sandborn^{1

2}

Affiliations

¹ Division of Gastroenterology, Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA.
² Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
³ Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, California, USA.
⁴ Department of Pathology, University of California San Diego, La Jolla, California, USA.

No abstract available

Publication types

Case Reports
Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Common Variable Immunodeficiency / complications
Common Variable Immunodeficiency / drug therapy*
Female
Gastrointestinal Agents / therapeutic use
Humans
Inflammation / complications
Inflammation / drug therapy*
Intestinal Diseases / complications
Intestinal Diseases / drug therapy*
Male
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
vedolizumab

Grants and funding

KL2 TR001444/TR/NCATS NIH HHS/United States